FDA v. ephedra: is it time to lift the ban?
Pyle
Kenneth R
KR
D019440:Anti-Obesity Agents / Q000009:adverse effects; D018687:Antidepressive Agents, Second-Generation; D019587:Dietary Supplements / Q000009:adverse effects; D004335:Drug and Narcotic Control; D029789:Ephedra / Q000009:adverse effects / Q000737:chemistry; D004809:Ephedrine / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007880:Legislation, Drug; D010380:Peer Review; D008517:Phytotherapy / Q000009:adverse effects; D028321:Plant Preparations / Q000009:adverse effects; D014364:Tryptophan; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D019440:Anti-Obesity Agents; D018687:Antidepressive Agents, Second-Generation; D028321:Plant Preparations; D014364:Tryptophan; D004809:Ephedrine